NVIDIA and Amgen have a research partnership focused on AI-accelerated drug discovery. Amgen uses NVIDIA BioNeMo AI models and GPU computing infrastructure to accelerate protein structure prediction, molecular docking simulations, and clinical trial data analysis. NVIDIA's $50M+ investment in Recursion Pharmaceuticals (a key Amgen research partner) deepens this pharmaceutical AI ecosystem.
Why it matters: Amgen spent $5B+ on R&D in 2024. AI-accelerated drug discovery can reduce the time from target identification to clinical candidate from 4-6 years to 18-24 months, potentially worth billions in first-mover advantages per approved drug. NVIDIA's partnership with Amgen represents the pharmaceutical industry's recognition that GPU computing is as transformative for drug discovery as for tech.
Amgen and Eli Lilly are direct competitors in the GLP-1 weight loss and diabetes drug market. Lilly's Mounjaro (tirzepatide) and Zepbound achieved blockbuster status rapidly, with combined revenue targeting $25B+ by 2025-2026. Amgen's MariTide (maridebart cafraglutide) is a monthly injectable GLP-1/GIPR dual agonist completing Phase 3 trials in 2025-2026, with FDA approval potentially in 2026-2027. Both companies are racing to capture the estimated $100B+ GLP-1 market opportunity as obesity treatment becomes a mainstream medical category.
Why it matters: Eli Lilly's Zepbound and Ozempic (Novo Nordisk) have created the fastest-growing drug category in pharmaceutical history. Amgen entered with a differentiated monthly injection approach vs. weekly injections for existing GLP-1s, targeting a more convenient dosing schedule as a competitive differentiator. Both companies are investing billions in manufacturing capacity expansion to address the severe supply shortage that constrained GLP-1 market penetration in 2023-2024. The GLP-1 market dynamics create both competitive pressure and market validation for Amgen's late-entry strategy.